Alnylam Pharmaceuticals, Inc. (ALNY) income statement
NASDAQ · Healthcare · Biotechnology · 2,500 employees · CEO Yvonne L. Greenstreet
- Price
- $165.00 -5.17%
- Market cap
- $22.1B
- Enterprise value
- $21.6B
- Last report
- Q3 '26 filed 2026-10-29
- Next report
- 2027-02-11 EPS est. $1.75
Alnylam Pharmaceuticals, Inc. (ALNY) reported revenue of $1.46B for Q3 '26 (+16.7% year on year), operating income of $346M (23.7% of revenue) and net income of $2.17B. Over the last four quarters revenue was $5.01B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $440M | $494M | $660M | $501M | $593M | $594M | $774M | $1.25B | $1.1B | $1.17B | $1.29B | $1.46B | |
| Cost of revenue | $85.9M | $66M | $68.7M | $85.9M | $103M | $71M | $143M | $197M | $268M | $211M | $298M | $362M | |
| Gross profit | $354M | $428M | $591M | $415M | $490M | $523M | $631M | $1.05B | $829M | $956M | $993M | $1.1B | |
| Research & development | $272M | $261M | $294M | $271M | $300M | $265M | $324M | $359M | $372M | $365M | $413M | $409M | |
| General & administrative | $198M | $211M | $248M | $221M | $295M | $240M | $323M | $322M | $325M | $323M | $0 | $342M | |
| Other operating expenses | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.92M | $0 | $0 | $190K | $0 | |
| Operating expenses | $470M | $472M | $543M | $492M | $596M | $505M | $647M | $684M | $698M | $687M | $761M | $751M | |
| Operating income | -$116M | -$43.4M | $48.6M | -$76.9M | -$105M | $18.1M | -$16.2M | $368M | $132M | $269M | $231M | $346M | |
| Interest income | $30.4M | $29.6M | $29.2M | $32.1M | $31M | $28.7M | $27.5M | $28.7M | $26.6M | $26.6M | $28.1M | $30.9M | |
| Interest expense | $31.3M | $35.3M | $33.3M | $34.4M | $39M | $38.6M | $40.2M | $44.4M | $129M | $69.3M | $82.1M | $84.4M | |
| Other non-operating income (gains on investments, FX ...) | -$10.1M | -$15.1M | $26.5M | -$2.62M | $49.8M | $21M | -$21.1M | $84.6M | -$159M | -$22.3M | $273K | -$34.4M | |
| Total non-operating income | -$21.3M | -$20.2M | -$59.8M | -$31.8M | -$88.8M | -$59.7M | -$19.2M | -$129M | $29.4M | -$47M | -$53.6M | -$50M | |
| Income before tax | -$138M | -$63.6M | -$11.2M | -$109M | -$194M | -$41.6M | -$35.4M | $239M | $161M | $222M | $178M | $296M | |
| Income tax | $183K | $2.35M | $5.72M | $2.91M | -$110M | $15.9M | $30.9M | -$12.1M | -$25.3M | -$15.7M | $13.3M | -$1.87B | |
| Net income | -$138M | -$65.9M | -$16.9M | -$112M | -$83.8M | -$57.5M | -$66.3M | $251M | $186M | $206M | $164M | $2.17B | |
| EPS (basic) | -$1.10 | -$0.52 | -$0.13 | -$0.87 | -$0.65 | -$0.44 | -$0.51 | $1.91 | $1.41 | $1.55 | $1.23 | $16.19 | |
| EPS (diluted) | -$1.10 | -$0.52 | -$0.13 | -$0.87 | -$0.65 | -$0.44 | -$0.51 | $1.84 | $1.37 | $1.51 | $1.20 | $15.72 | |
| Shares (basic, weighted) | 126M | 126M | 127M | 129M | 129M | 130M | 130M | 131M | 132M | 133M | 133M | 134M | |
| Shares (diluted, weighted) | 126M | 126M | 127M | 129M | 129M | 130M | 130M | 137M | 136M | 138M | 138M | 138M | |
| Depreciation & amortization | $13.5M | $13.5M | $15M | $14M | $14.2M | $14.4M | $13.9M | $13.8M | $13.5M | $13.6M | $13.9M | $14.5M | |
| EBITDA | -$92.9M | -$14.8M | $37.1M | -$60.3M | -$141M | $11.5M | $18.8M | $297M | $304M | $304M | $245M | $395M |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $47.2M | $89.9M | $74.9M | $220M | $493M | $844M | $1.04B | $1.83B | $2.25B | $3.71B | |
| Cost of revenue | $0 | $13.4M | $1.8M | $25.1M | $78.1M | $140M | $169M | $310M | $323M | $677M | |
| Gross profit | $47.2M | $76.5M | $73.1M | $195M | $415M | $704M | $869M | $1.52B | $1.92B | $3.04B | |
| Research & development | $382M | $391M | $505M | $655M | $655M | $792M | $883M | $1B | $1.13B | $1.32B | |
| General & administrative | $89.4M | $199M | $382M | $479M | $588M | $621M | $771M | $796M | $976M | $0 | |
| Other operating expenses | $0 | -$3.02M | $4.17M | $0 | $0 | -$2.05M | $0 | $0 | $0 | $0 | |
| Operating expenses | $472M | $590M | $888M | $1.13B | $1.24B | $1.41B | $1.65B | $1.8B | $2.1B | $2.54B | |
| Operating income | -$425M | -$500M | -$815M | -$939M | -$828M | -$709M | -$785M | -$282M | -$177M | $502M | |
| Interest income | $8.31M | $12.2M | $29.3M | $33.4M | $11.8M | $1.58M | $24.8M | $95.6M | $122M | $111M | |
| Interest expense | $0 | $0 | $0 | $0 | $84.5M | $143M | $156M | $121M | $142M | $253M | |
| Other non-operating income (gains on investments, FX ...) | $0 | $0 | -$54M | -$54.2M | -$57.3M | $471K | $186M | $30.1M | $58.6M | -$74.2M | |
| Total non-operating income | $14.5M | $9.21M | $54M | $54.2M | -$27.2M | -$143M | -$342M | -$151M | -$200M | -$178M | |
| Income before tax | -$410M | -$491M | -$761M | -$885M | -$856M | -$852M | -$1.13B | -$434M | -$377M | $323M | |
| Income tax | $0 | $0 | $823K | $863K | $2.68M | $680K | $4.16M | $6.73M | -$99.2M | $9.41M | |
| Net income | -$410M | -$491M | -$761M | -$886M | -$858M | -$853M | -$1.13B | -$440M | -$278M | $314M | |
| EPS (basic) | -$4.79 | -$5.42 | -$7.57 | -$8.11 | -$7.46 | -$7.20 | -$9.30 | -$3.52 | -$2.18 | $2.39 | |
| EPS (diluted) | -$4.79 | -$5.42 | -$7.57 | -$8.11 | -$7.46 | -$7.20 | -$9.30 | -$3.52 | -$2.18 | $2.33 | |
| Shares (basic, weighted) | 85.6M | 90.6M | 101M | 109M | 115M | 118M | 122M | 125M | 128M | 131M | |
| Shares (diluted, weighted) | 85.6M | 90.6M | 101M | 109M | 115M | 118M | 122M | 125M | 128M | 135M | |
| Depreciation & amortization | $15.1M | $13.4M | $6.44M | $54.4M | $74.4M | $47.6M | $44.5M | $54.1M | $56.7M | $55.7M | |
| EBITDA | -$409M | -$488M | -$754M | -$831M | -$697M | -$662M | -$927M | -$258M | -$179M | $631M |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-02